LadRx Valuation

Is LADX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LADX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LADX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LADX's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for LADX?

Key metric: As LADX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for LADX. This is calculated by dividing LADX's market cap by their current book value.
What is LADX's PB Ratio?
PB Ratio-0.2x
Book-US$1.75m
Market CapUS$297.06k

Price to Book Ratio vs Peers

How does LADX's PB Ratio compare to its peers?

The above table shows the PB ratio for LADX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.4x
TCBP TC Biopharm (Holdings)
0.2xn/aUS$328.8k
NEXI NexImmune
0.8xn/aUS$571.8k
CAPS Capstone Holding
0.2xn/aUS$504.4k
BLPH Bellerophon Therapeutics
0.2xn/aUS$672.8k
LADX LadRx
n/an/aUS$297.1k

Price-To-Book vs Peers: LADX has negative equity and a Price-To-Book Ratio (-0.2x) compared to the peer average (0.4x).


Price to Book Ratio vs Industry

How does LADX's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$586.33m
AMRN Amarin
0.4x-7.7%US$202.38m
IMAB I-Mab
0.4x1.8%US$77.50m
MGX Metagenomi
0.3x-23.2%US$75.60m
LADX is unprofitableIndustry Avg. 1.9xNo. of Companies72PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: LADX has negative equity and a Price-To-Book Ratio (-0.2x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is LADX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LADX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-0.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LADX's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies